Cargando…
P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621474/ http://dx.doi.org/10.1097/01.HS9.0000890812.66186.e8 |
| _version_ | 1784821563644706816 |
|---|---|
| author | Borchmann, Peter Johnson, Nathalie A. Lavie, David Gregory, Gareth Herrera, Alex F. Minuk, Leonard Vucinic, Vladan Armand, Philippe Avigdor, Abraham Gasiorowski, Robin Herishanu, Yair Keane, Colm Kuruvilla, John Palcza, John Pillai, Pallavi Nahar, Akash Timmerman, John |
| author_facet | Borchmann, Peter Johnson, Nathalie A. Lavie, David Gregory, Gareth Herrera, Alex F. Minuk, Leonard Vucinic, Vladan Armand, Philippe Avigdor, Abraham Gasiorowski, Robin Herishanu, Yair Keane, Colm Kuruvilla, John Palcza, John Pillai, Pallavi Nahar, Akash Timmerman, John |
| author_sort | Borchmann, Peter |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621474 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96214742022-11-01 P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Borchmann, Peter Johnson, Nathalie A. Lavie, David Gregory, Gareth Herrera, Alex F. Minuk, Leonard Vucinic, Vladan Armand, Philippe Avigdor, Abraham Gasiorowski, Robin Herishanu, Yair Keane, Colm Kuruvilla, John Palcza, John Pillai, Pallavi Nahar, Akash Timmerman, John Hemasphere Immunotherapy Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621474/ http://dx.doi.org/10.1097/01.HS9.0000890812.66186.e8 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Immunotherapy Borchmann, Peter Johnson, Nathalie A. Lavie, David Gregory, Gareth Herrera, Alex F. Minuk, Leonard Vucinic, Vladan Armand, Philippe Avigdor, Abraham Gasiorowski, Robin Herishanu, Yair Keane, Colm Kuruvilla, John Palcza, John Pillai, Pallavi Nahar, Akash Timmerman, John P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
| title | P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
| title_full | P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
| title_fullStr | P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
| title_full_unstemmed | P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
| title_short | P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
| title_sort | p061: safety and dose-expansion study of combination favezelimab (anti–lag-3) plus pembrolizumab in anti–pd-1–naive patients with relapsed or refractory classical hodgkin lymphoma |
| topic | Immunotherapy |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621474/ http://dx.doi.org/10.1097/01.HS9.0000890812.66186.e8 |
| work_keys_str_mv | AT borchmannpeter p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT johnsonnathaliea p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT laviedavid p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT gregorygareth p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT herreraalexf p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT minukleonard p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT vucinicvladan p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT armandphilippe p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT avigdorabraham p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT gasiorowskirobin p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT herishanuyair p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT keanecolm p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT kuruvillajohn p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT palczajohn p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT pillaipallavi p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT naharakash p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT timmermanjohn p061safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphoma |